Who are Mebendazole polymorph C's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel injection, Administration of Albendazole on Day 1, Paclitaxel protein bound, Docetaxel (D), Docetaxel or albumin paclitaxel, VLI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mebendazole-polymorph-c.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Mebendazole polymorph C — Competitive Intelligence Brief

Mebendazole polymorph C (Mebendazole polymorph C) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzimidazole anthelmintic. Area: Infectious Disease / Parasitology.

phase 3 Benzimidazole anthelmintic β-tubulin Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

Mebendazole polymorph C (Mebendazole polymorph C) — University of Kelaniya. Mebendazole polymorph C inhibits microtubule assembly in parasitic worms by binding to β-tubulin, disrupting their motility and nutrient uptake.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mebendazole polymorph C TARGET	Mebendazole polymorph C	University of Kelaniya	phase 3	Benzimidazole anthelmintic	β-tubulin
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
Administration of Albendazole on Day 1	Administration of Albendazole on Day 1	London School of Hygiene and Tropical Medicine	marketed	Benzimidazole anthelmintic	β-tubulin
Paclitaxel protein bound	Paclitaxel protein bound	Barts & The London NHS Trust	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Docetaxel (D)	Docetaxel (D)	BeyondSpring Pharmaceuticals Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin
Docetaxel or albumin paclitaxel	Docetaxel or albumin paclitaxel	Shandong Cancer Hospital and Institute	marketed	Taxane; microtubule-stabilizing chemotherapy agent	β-tubulin (microtubule)
VLI	VLI	Spectrum Pharmaceuticals, Inc	marketed	Vinca alkaloid	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzimidazole anthelmintic class)

Lihir Medical Centre · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
Universidad Nacional de Salta · 1 drug in this class
University of Kelaniya · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mebendazole polymorph C — Competitive Intelligence Brief. https://druglandscape.com/ci/mebendazole-polymorph-c. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab